[steve86]

A case report has highlighted the potential of trastuzumab deruxtecan (T-DXd) as a treatment for aggressive prostate cancer. A 60-year-old Air Force veteran with stage four metastatic prostate cancer, who had not responded to several therapies, showed significant improvement after being treated off-label with T-DXd in February 2024. This treatment, typically used for HER2-expressing cancers like breast cancer, was the first known use in prostate cancer. After four cycles, the patient experienced a 57% reduction in tumor volume and significant clinical improvement, defying previous expectations. The case underscores the importance of HER2 testing in advanced prostate cancer for identifying candidates for targeted therapies.

[ConservativeMind]

Nicely edited further down.

Thank you.